Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm Altamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures AAA is a localized abnormal enlargement (bulge) of the abdominal aorta, i.e. the part of the main artery which runs through the belly. Th ...

Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic aneurysm Altamira's SemaPhore™ nanoparticles delivering SOD2 mRNA successfully to mitochondria in aorta wall Positive outcomes suggest potential use of treatment in management of small abdominal aortic aneurysm and prevention of ruptures "Using SOD2 mRNA to modulate oxidative stress appears a very promising approach in various challenging cardiovascular disorders such as a ...

Even in case of a successful physical repositioning procedure, patients may experience residual dizziness. This may last for a few days up to several weeks and may affect quality of life and be of incapacitating nature. Residual dizziness may be due to, among others, remaining otoconia, incomplete vestibular compensation or microcirculation dysfunction. Based on their review of available treatment options, the authors of the publication suggest the use of vestibular habituation therapies and vestibular reha ...

Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- BPPV is characterized by repeated episodes of vertigo produced by changes in the head position relative to gravity, e.g. when tipping the head backward. It is typically caused by dislodged inner ear particles (otoconia) in one of the semicircular canals, most often the posterior canal. The debris elicits unwanted vestibular stimulation and is often cleared through physical repositioning procedures such as the Epley maneuver, which is strongly recommended ...

Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indications Streamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RN ...

Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indications Streamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RN ...

Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 - - Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the ...

Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 - - Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the ...

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery  Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (US ...

Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated by statistically significant improvement in health-related quality of life and reduced need for relief medicationStudy outcomes support plans for further international expansion HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeutics Ltd. ( ...